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179 Abstract Aims/hypothesis: Recent European guidelines for non-alcoholic
fatty l iver disease (NAFLD) call for reference values for HOMA-IR. In
this study, we aimed to determine: (1) the upper l imit of normal
HOMA-IR in two population-based cohorts; (2) the HOMA-IR
corresponding to NAFLD; (3) the effect of sex and PNPLA3
genotype at rs738409 on HOMA-IR; and (4) inter-laboratory
variations in HOMA-IR.
Methods: We identified healthy individuals in two
population-based cohorts (FINRISK 2007 [n = 5024] and the
Programme for Prevention of Type 2 Diabetes in Finland [FIN-D2D;
n = 2849]) to define the upper 95th percentile of HOMA-IR.
Non-obese individuals with normal fasting glucose levels, no
excessive alcohol use, no known diseases and no use of any drugs
were considered healthy. The optimal HOMA-IR cut-off for NAFLD
(liver fat ≥5.56%, based on the Dallas Heart Study) was determined
in 368 non-diabetic individuals (35% with NAFLD), whose liver fat
was measured using proton magnetic resonance spectroscopy
(1H-MRS). Samples from ten individuals were simultaneously
analysed for HOMA-IR in seven European laboratories.
Results: The upper 95th percentiles of HOMA-IR were 1.9 and 2.0
in healthy individuals in the FINRISK (n = 1167) and FIN-D2D
(n = 459) cohorts. Sex or PNPLA3 genotype did not influence these
values. The optimal HOMA-IR cut-off for NAFLD was 1.9 (sensitivity
87%, specificity 79%). A HOMA-IR of 2.0 corresponded to normal
liver fat (<5.56% on 1H-MRS) in l inear regression analysis. The 2.0
HOMA-IR measured in Helsinki corresponded to 1.3, 1.6, 1.8, 1.8,
2.0 and 2.1 in six other laboratories. The inter-laboratory CV% of
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HOMA-IR was 25% due to inter-assay variation in insulin (25%)
rather than glucose (5%) measurements.
Conclusions/interpretation: The upper l imit of HOMA-IR in
population-based cohorts closely corresponds to that of normal l iver
fat. Standardisation of insulin assays would be the first step towards
definition of normal values for HOMA-IR.
180 Keywords
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15 Abstract
16 Aims/hypothesis Recent European guidelines for non-
17 alcoholic fatty liver disease (NAFLD) call for reference values
18 for HOMA-IR. In this study, we aimed to determine: (1) the
19 upper limit of normal HOMA-IR in two population-based
20 cohorts; (2) the HOMA-IR corresponding to NAFLD; (3)
21the effect of sex and PNPLA3 genotype at rs738409 on
22HOMA-IR; and (4) inter-laboratory variations in HOMA-IR.
23Methods We identified healthy individuals in two
24population-based cohorts (FINRISK 2007 [n = 5024]
25and the Programme for Prevention of Type 2 Diabetes in
26Finland [FIN-D2D; n = 2849]) to define the upper 95th
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27 percentile of HOMA-IR. Non-obese individuals with nor-
28 mal fasting glucose levels, no excessive alcohol use, no
29 known diseases and no use of any drugs were considered
30 healthy. The optimal HOMA-IR cut-off for NAFLD (liver
31 fat ≥5.56%, based on the Dallas Heart Study) was deter-
32 mined in 368 non-diabetic individuals (35% with
33 NAFLD), whose liver fat was measured using proton
34 magnetic resonance spectroscopy (1H-MRS). Samples
35 from ten individuals were simultaneously analysed for
36 HOMA-IR in seven European laboratories.
37 Results The upper 95th percentiles of HOMA-IR were 1.9
38 and 2.0 in healthy individuals in the FINRISK (n = 1167)
39 and FIN-D2D (n = 459) cohorts. Sex or PNPLA3 genotype
40 did not influence these values. The optimal HOMA-IR cut-
41 off for NAFLD was 1.9 (sensitivity 87%, specificity 79%).
42 A HOMA-IR of 2.0 corresponded to normal liver fat
43 (<5.56% on 1H-MRS) in linear regression analysis. The
44 2.0 HOMA-IR measured in Helsinki corresponded to 1.3,
45 1.6, 1.8, 1.8, 2.0 and 2.1 in six other laboratories. The
46 inter-laboratory CV% of HOMA-IR was 25% due to
47 inter-assay variation in insulin (25%) rather than glucose
48 (5%) measurements.
49 Conclusions/interpretation The upper limit of HOMA-IR
50 in population-based cohorts closely corresponds to that
51 of normal liver fat. Standardisation of insulin assays
52 would be the first step towards definition of normal
53 values for HOMA-IR.
54 Keywords Insulin . Liver fat . NAFLD .PNPLA3 .
55 Reference values
56 Abbreviations
58 ALT9 Alanine aminotransferase
60 AST1 Aspartate aminotransferase
62 AUROC3 Area under the receiver operating
64 characteristic (curve)
65 DHS6 Dallas Heart Study
67 DILGOM8 Dietary Lifestyle and Genetic Determinants
69 of the Development of Obesity and Metabolic
70 Syndrome study
71 FIN-D2D2 Programme for Prevention of Type 2
73 Diabetes in Finland
74 GGT5 γ-Glutamyltransferase
76
1H-MRS7 Proton magnetic resonance spectroscopy
78 NAFLD9 Non-alcoholic fatty liver disease
80 NPV1 Negative predictive value
82 PNPLA33 Patatin-like phospholipase
84 domain-containing protein 3
85 PPV6 Positive predictive value
87 ROC8 Receiver operating characteristic
89
90Introduction
91Insulin resistance in individuals with non-alcoholic fatty liver
92disease (NAFLD) is characterised by reduced whole body,
93hepatic and adipose tissue insulin sensitivity [1, 2]. The liver,
94once insulin resistant, overproduces glucose that stimulates
95insulin secretion, resulting in mild hyperglycaemia and
96hyperinsulinaemia. Therefore, the product of fasting glucose
97and fasting insulin divided by a constant (i.e. HOMA-IR) [3]
98is a good surrogate for insulin sensitivity in non-diabetic indi-
99viduals [3–5]. Once the glucose concentration reaches the di-
100agnostic threshold for type 2 diabetes, the insulin concentra-
101tion starts to decline relative to glucose [6–9] and HOMA-IR
102no longer exclusively reflects insulin sensitivity.
103A recent joint European practice guideline for NAFLD [10]
104concluded: ‘HOMA-IR provides a surrogate estimate of insu-
105lin resistance in persons without diabetes and can therefore be
106recommended, provided proper reference values have been
107established.’ A reference value can be defined as the mean +
1082 SDs for normally distributed variables or the 95th percentile
109for non-normally distributed variables of a population-based
110sample [11, 12]. Definition of health then becomes dependent
111on the underlying population. This is particularly relevant for
112HOMA-IR, as obesity is highly prevalent and perhaps the
113single most important cause of variation in insulin [13].
114Thus, for HOMA-IR, it would seem wiser to use reference
115values derived from healthy individuals, although definitions
116of health can also vary [14–16]. Pre-analytical causes of var-
117iation should also be considered [3, 4], and the inter-assay
118variation of insulin [17] and glucose should be known.
119Normal liver fat content, measured using proton magnetic
120resonance spectroscopy (1H-MRS), was determined in the
121population-based Dallas Heart Study (DHS) [18]. In healthy
122individuals (BMI <25 kg/m2, no diabetes, normal fasting glu-
123cose levels, low alcohol consumption, no known liver disease
124or risk factors for liver disease and normal alanine aminotrans-
125ferase [ALT] levels; n = 345), the 95th percentile for liver fat
126content was 5.56%. It is unknown how HOMA-IR relates to
127this amount of liver fat and whether this definition of normal
128liver fat reflects what normal liver fat is elsewhere. The I148M
129variant of the gene encoding patatin-like phospholipase
130domain-containing protein 3 (PNPLA3) (rs738409 c.444
131C>G, p.I148M) has a prevalence of 30–50% [19]. It increases
132the risk of NAFLD, but not of insulin resistance [20]. The
133impact of this gene variant on reference values for HOMA-
134IR has not been studied.
135In the present study, we aimed to determine: (1) the upper
13695th percentile of HOMA-IR in two population-based co-
137horts; (2) the HOMA-IR that best distinguishes between
138NAFLD and normal liver fat content, as quantified by 1H-
139MRS in a cohort of non-diabetic individuals; (3) whether
140sex or the PNPLA3 genotype at rs738409 influences reference
141values for HOMA-IR; and (4) the inter-laboratory variation in
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142 HOMA-IR among European centres participating in the
143 Elucidating Pathways of Steatohepatitis (EPoS) consortium
144 (www.epos-nafld.eu).
145 Methods
146 Study designs
147 Population-based cohorts for the determination of normal
148 HOMA-IRTo determine normal HOMA-IR, we studied non-
149 pregnant adults in two population-based cohorts: the National
150 FINRISK 2007/ Dietary Lifestyle and Genetic Determinants
151 of the Development of Obesity and Metabolic Syndrome
152 study (DILGOM) study (n = 5024), conducted by the
153 National Institute for Health and Welfare in Finland between
154 January and July 2007 [21]; and the Programme for
155 Prevention of Type 2 Diabetes in Finland (FIN-D2D)
156 (n = 2849), conducted between October and December 2007
157 [22] (see electronic supplementary material [ESM] Methods
158 and ESM Fig. 1). The definition of healthy was as in the
159 population-based DHS [18]: (1) alcohol use <30 g/day in
160 men and <20 g/day in women; (2) no diabetes, based on his-
161 tory and normal fasting plasma glucose levels (<6.1 mmol/l);
162 (3) BMI <25 kg/m2; (4) no regular use of drugs; and (5) no
163 clinical or biochemical evidence of liver or other disease, as
164 defined by history and biochemical examinations.
165 Liver fat cohort Participants for the liver fat cohort were
166 recruited using newspaper advertisements, by contacting oc-
167 cupational health services and from individuals referred to the
168 Department of Gastroenterology, Helsinki University Hospital
169 (Helsinki, Finland), because of chronically elevated serum
170 transaminase concentrations using the following inclusion
171 criteria: (1) age 18–75 years; (2) no known acute or chronic
172 disease except obesity, hypertension or NAFLD based on
173 medical history, physical examination, standard laboratory
174 tests and ECG; (3) non-diabetic based on a fasting plasma
175 glucose level of ≤6.9 mmol/l; and (4) alcohol consumption
176 of ≤20 g per day in women and ≤30 g in men [23]. Study
177 physicians assessed alcohol intake using the same question-
178 naire as in the population-based studies. Exclusion criteria
179 included: (1) pregnancy; (2) serologic evidence of hepatitis
180 B/C or autoimmune hepatitis; (3) clinical signs or symptoms
181 of inborn errors of metabolism; (4) a history of predisposition
182 to toxins; (5) use of drugs associated with liver steatosis; and
183 (6) use of antihypertensive drugs or other drugs possibly
184 influencing glucose metabolism. The study protocol was ap-
185 proved by the ethics committee of the Helsinki University
186 Central Hospital and was carried out in accordance with the
187 Declaration of Helsinki. Each participant provided written in-
188 formed consent.
189Inter-laboratory variation in insulin assays Ten non-
190diabetic individuals covering a wide range of insulin sensitiv-
191ities were recruited. The participants were healthy based on
192medical history, physical examination and standard laboratory
193tests, but eight of them were overweight or obese (BMI
194≥25 kg/m2). Blood was drawn in Helsinki after a 12 h fast
195for measurement of fasting insulin, glucose, HDL-cholesterol,
196LDL-cholesterol, total cholesterol, triacylglycerol, aspartate
197aminotransferase (AST), ALT, γ-glutamyltransferase (GGT),
198ferritin and albumin. Measurements of laboratory variables
199other than insulin or glucose were performed for comparison
200to estimate their inter-assay CVs. The fresh samples were
201analysed immediately in Helsinki. To study the effect of freez-
202ing, another set of samples were immediately frozen to −80°C
203and then melted and assayed on the same day in Helsinki. To
204study the effect of time, a third set of samples were frozen to
205−80°C and assayed after 2 weeks in Helsinki. At this same
206time point, six additional sets of samples, which had been
207shipped in dry ice, were assayed in Newcastle (UK), Paris
208(France), Pisa (clinical and research laboratories; Italy),
209Torino (Italy) and Mainz (Germany). The study protocol was
210approved by the ethics committee of the Helsinki University
211Central Hospital and was carried out in accordance with the
212Declaration of Helsinki. Each participant provided written in-
213formed consent.
214Biochemical measurements
215FINRISK/DILGOM and FIN-D2D Biochemical assays
216were performed in the Laboratory of Analyt ical
217Biochemistry of the Institute of Health and Welfare
218(Helsinki, Finland) using an Architect ci8200 analyser
219(Abbott Laboratories, Abbott Park, IL, USA). Plasma glucose
220was determined using the hexokinase method (Abbott
221Laboratories) and serum insulin using a chemiluminescent
222microparticle immunoassay (Abbott Laboratories). Serum to-
223tal cholesterol, HDL-cholesterol and triacylglycerol concen-
224trations were measured using enzymatic kits (Abbott
225Laboratories), and the LDL-cholesterol concentration was cal-
226culated using the Friedewald formula [24]. Total cholesterol
227was measured using the CHOD-PAP assay (Abbott
228Laboratories). Samples were stored at −80°C before analysis.
229In the FIN-D2D study, HbA1c was measured using an
230immunoturbidimetric method (Abbott Laboratories), and se-
231rum ALT, AST and GGTconcentrations were measured using
232International Federation of Clinical Chemistry photometric
233methods (Abbott Laboratories). In the liver fat cohort, plasma
234glucose was measured using the hexokinase method in an
235autoanalyser (Roche Diagnostics Hitachi 917; Hitachi,
236Tokyo, Japan) and serum insulin was measured in fresh serum
237samples using a time-resolved fluoroimmunoassay with
238AutoDELFIA kits (Wallac, Turku, Finland). HbA1c was mea-
239sured using HPLC using the fully automated analyser system
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240 (Bio-Rad, Richmond, CA, USA). Serum triacylglycerol, total
241 cholesterol, LDL-cholesterol and HDL-cholesterol concentra-
242 tions were measured with enzymatic kits from Roche
243 Diagnostics using an autoanalyser (Roche Diagnostics
244 Hitachi 917; Hitachi). Serum ALT, AST and GGT activities
245 were determined as recommended by the European
246 Committee for Clinical Laboratory Standards using the
247 Roche Diagnostics Hitachi 917 (Hitachi). HOMA-IR was cal-
248 culated as described by Matthews et al [3]. The methods used
249 by the seven participating centres for HOMA-IR and the other
250 laboratory variables are shown in ESM Methods.
251 Genotyping of PNPLA3 at rs738409
252 FINRISK/DILGOM The PNPLA3 genotype was deter-
253 mined from 1000G imputed genome-wide association study
254 data consisting of three subsets genotyped using the Illumina
255 HumanCoreExome, Illumina OmniExpress and Illumina
256 610K (Illumina, San Diego, CA, USA).
257 FIN-D2D Genomic DNA was extracted from whole blood
258 using automated Chemagen DNA extraction equipment
259 (PerkinElmer, Waltham, MA, USA) or a QIAamp DNA
260 Blood Maxi Kit (Qiagen, Hilden, Germany) following the
261 protocol of the kit with slight modifications. Genotyping
262 was performed using a TaqMan assay (Applied Biosystems,
263 Paisley, UK).
264 Liver fat cohortDNAwas isolated from whole blood and the
265 PNPLA3 genotype at rs738409 was determined as previously
266 described using a TaqMan assay (Applied Biosystems) [25].
267 Measurement of liver fat content by 1H-MRS
268 Liver fat was measured by using 1H-MRS as previously de-
269 scribed [23]. Liver fat content was expressed as a mass frac-
270 tion in percentage units [23]. NAFLD was defined as in the
271 DHS (liver fat ≥5.56% by 1H-MRS) [18].
272 Other measurements
273 In all cohorts, body weight, height, BMI and waist and
274 hip circumferences were measured as previously de-
275 scribed [23, 26, 27].
276 Statistical analysis
277 Distribution of continuous variables was analysed for normal-
278 ity using the Kolmogorov–Smirnov test. Data are shown as
279 means ± SD for normally distributed data and as medians (25–
280 75%) for non-normally distributed data. To compare charac-
281 teristics among groups, the unpaired t test and the Mann–
282 Whitney U test were used for continuous variables, and
283Fisher’s exact test and the χ2 test were used for categorical
284variables, where appropriate. Logarithmic transformation was
285performed for non-normally distributed data if needed.
286Correlation analyses were performed using Pearson’s correla-
287tion coefficient.
288Healthy individuals in the FINRISK/DILGOM (n = 1167)
289and FIN-D2D (n = 459) cohorts were identified. HOMA-IR
290was not normally distributed, and therefore the 95th percentile
291(90% CI) rather than the mean + 2 SD was used to determine
292the upper reference value for HOMA-IR [12]. After log2 trans-
293formation, HOMA-IR values were adjusted in a generalised
294linear model, using age and BMI as covariates.
295We used twomethods to identify a cut-off value of HOMA-
296IR for NAFLD. First, we calculated the HOMA-IR value that
297corresponded to the normal liver fat content based on the DHS
298(liver fat <5.56% [18]) using linear regression analysis. We
299tested whether the slopes and intercepts in linear regression
300analysis differed between men and women, and carriers and
301non-carriers of the PNPLA3 I148M variant. The 95th percen-
302tile was used to define normal liver fat content in healthy
303individuals in the liver fat cohort, as in the DHS [18].
304Second, we determined the receiver operating characteristic
305(ROC) curve to calculate the area under the ROC curve
306(AUROC [95% CI]). The Youden index [28] was used to
307identify the optimal cut-off of HOMA-IR. For this, individuals
308were randomly divided into discovery (two-thirds of the
309individuals) and validation (one-third) groups. The discovery
310group was used to determine the ROC curve for HOMA-IR.
311The validation group and all individuals were used for valida-
312tion. For additional validation, we generated 1000 random sets
313of samples and used the bootstrap method to validate the
314model in the sample sets. The AUROC of each set was esti-
315mated, and the average of these estimates provided the overall
316prediction accuracy of the model. Power analysis was con-
317ducted to estimate the appropriate sample size for correlation
318analysis and ROC analysis. To detect a correlation coefficient
319of 0.2 between HOMA-IR and liver fat content with a power
320of 0.8, a sample size of at least 193 was required. By setting
321the ratio of sample sizes between negative and positive groups
322at 2, at least 23 cases and 46 control participants were needed
323to reach a statistical power of 0.8 to detect the minimum
324AUROC of 0.7.
325The inter-laboratory CVs of fasting insulin, glucose,
326HOMA-IR, lipids, liver enzymes, ferritin and albumin among
327laboratories were calculated. Linear regression analyses were
328performed to compare insulin, glucose and HOMA-IR mea-
329surements in Helsinki to those in other centres. The HOMA-
330IR in each centre corresponding to the upper limit of normal
331HOMA-IR in Helsinki was defined from linear regression
332equations.
333We considered a p value of <0.05 to be statistically signif-
334icant. Calculations were made using R Project for Statistical
335Computing version 3.1.1 (www.r-project.org, Vienna,
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336 Austria) and GraphPad Prism version 6.00 for Mac OS X
337 (GraphPad Software, San Diego, CA, USA).
338 Results
339 Reference values for HOMA-IR in two population-based
340 cohorts
341 Characteristics of the healthy individuals in the two
342 population-based cohorts (n = 1167 in FINRISK/DILGOM,
343 n = 459 in FIN-D2D) are shown in Table 1. Characteristics of
344 these individuals subgrouped based on their PNPLA3 geno-
345 type at rs738409 are shown in ESM Table 1. The upper limit
346 of normal (95th percentile [90% CI]) HOMA-IR was 1.9 (1.8,
347 2.0) in the FINRISK/DILGOM cohort and 2.0 (1.9, 2.2) in the
348 FIN-D2D cohort (Fig. 1).
349 There was no sex difference among HOMA-IRs in either
350 cohort (Fig. 1). Since there were slight differences in age and
351 BMI between men and women in the two studies (Table 1) we
352 also calculated age- and BMI-adjusted HOMA-IRs, which
353 were very similar to the unadjusted values (Table 1). The
354 PNPLA3 genotype did not influence HOMA-IR in either co-
355 hort (Fig. 1).
356 The 95th percentile of serum ALT in the FIN-D2D cohort
357 was 31 U/l in women and 43 U/l in men. In the FINRISK/
358 DILGOM cohort aged 25–74 years, age weakly inversely cor-
359 related with HOMA-IR (ρ = −0.16, p < 0.001). No significant
360 relationship was observed between age and HOMA-IR in the
361 FIN-D2D cohort aged 45–74 years (ρ = 0.06, p = 0.21).
362 Relationship between HOMA-IR and liver fat content
363 Characteristics of the non-diabetic individuals in the liver fat
364 cohort (n = 368) are shown in Table 1. Of them, 35% had
365 NAFLD as evaluated by 1H-MRS. Liver fat percentage posi-
366 tively correlated with HOMA-IR (r = 0.67, p < 0.001)
367 (Fig. 2a). Normal liver fat, defined as in the DHS (<5.56%),
368 corresponded to a HOMA-IR of 2.0 (95% CI 1.9, 2.1)
369 (Fig. 2a) in non-diabetic individuals, with a HOMA-IR of
370 1.9 (1.8, 2.1) in women and 2.1 (1.9, 2.2) in men (p = 0.29).
371 The HOMA-IR corresponding to the normal liver fat content
372 (<5.56%) was significantly higher in non-carriers (2.1 [2.0,
373 2.2]) than carriers (1.8 [1.6, 1.9], p = 0.007) of the PNPLA3
374 I148M variant (Fig. 2b) (i.e. the variant allele carriers had a
375 higher liver fat content for any given HOMA-IR than non-
376 carriers). The upper 95th percentile for liver fat in the 96
377 healthy individuals was 5.9%.
378 The discovery and validation groups for defining the
379 HOMA-IR cut-off for NAFLD were similar with respect to
380 clinical and biochemical characteristics (ESM Table 2). The
381 AUROC for HOMA-IR was 0.88 (95% CI 0.84, 0.92) in the
382 discovery group (Fig. 3). The optimal HOMA-IR cut-off for
383NAFLD, based on the Youden index, the point of optimal
384sensitivity and specificity, was 1.9. This cut-off had a sensi-
385tivity of 87%, specificity of 79%, negative predictive value
386(NPV) of 92% and positive predictive value (PPV) of 67%.
387The results were similar for the validation group (AUROC
3880.80 [0.70, 0.88], sensitivity 68%, specificity 82%, NPV
38981% and PPV 70%) and for all individuals (AUROC 0.85
390[0.80, 0.89] sensitivity 80%, specificity 80%, NPV 88% and
391PPV 68%) (Fig. 3). The AUROC for bootstrap samples was
3920.88 (0.82, 0.92) and the overall estimate of optimism was
3930.00079. Neither sex (p = 0.22) nor PNPLA3 genotype
394(p = 0.18) significantly influenced the AUROC.
395Inter-laboratory variation in insulin assays
396and HOMA-IR
397The ten individuals (three men, seven women) recruited to
398investigate inter-laboratory variations ranged in age from 22
399to 62 years and in BMI from 21.3 to 42.4 kg/m2. Among the
400seven laboratories, the mean values ranged from 18.0 to
40191.2 pmol/l for insulin, from 4.7 to 6.1 mmol/l for glucose
402and from 0.69 to 4.0 for HOMA-IR. Freezing and thawing
403the serum on the same day had no impact on fasting insulin
404(52.8 ± 28.8 vs 54.0 ± 29.4 pmol/l, p = 0.077). Serum insulin
405concentrations decreased over time when stored at −80°C de-
406grees for 2 weeks (54.0 ± 29.4 vs 45.6 ± 25.8 pmol/l,
407p = 0.005).
408The CVof fasting insulin measured in the seven participat-
409ing laboratories after 2 weeks of storage at −80°C averaged
41025.4%. The CVof fasting glucose was significantly lower and
411averaged 4.6%. The CV of HOMA-IR was 25.0%. The
412HOMA-IR value of 2.0, as measured in Helsinki,
413corresponded to HOMA-IRs of 1.3, 1.6, 1.8, 1.8, 2.0 and 2.1
414in the six other centres (Fig. 4). The relationships between
415insulin and glucose measurements in Helsinki vs the other
416centres are shown in ESM Fig. 2, 3.
417The inter-laboratory CVs for the other analytes were as
418follows: total cholesterol 7.4%, LDL-cholesterol 12.8%,
419HDL-cholesterol 7.0%, triacylglycerol 8.3%, AST 11.7%,
420ALT 11.6%, GGT 11.3%, ferritin 19.1% and albumin 7.7%.
421All of these CVs, with the exception of ferritin, were signifi-
422cantly lower than the CV for fasting insulin (p < 0.01).
423Discussion
424The present studies were undertaken to determine whether a
425single value of HOMA-IR could be used to clearly identify
426individuals with NAFLD, and how HOMA-IRs determined
427by different laboratories in European countries compare with
428each other. In two population-based cohorts, the upper limits
429of normal HOMA-IR were 1.9 and 2.0. In individuals whose
430liver fat content was determined using 1H-MRS, a HOMA-IR
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t1:1 Table 1 Participant characteristics
t1:2 Variable FINRISK/DILGOM FIN-D2D Liver fat cohort
t1:3 All (n = 1167) Women
(n = 798)
Men (n = 369) All (n = 459) Women
(n = 308)
Men (n = 151) All (n = 368) Women
(n = 221)
Men (n = 147)
t1:4 Age (years) 44 (35–56) 43 (33–53) 47 (36–56)** 55 (50–62) 55 (50–62) 57 (50–65) 42 (28–52) 42 (32–52) 41 (27–51)
t1:5 Weight (kg) 63.4
(57.8–69.9)
60.2
(55.6–64.8)
72.2
(67.0–76.6)***
63.6
(58.3–70.0)
61.0
(55.7–64.9)
72.7
(67.9–76.7)***
83.4
(24.5–33.2)
81.4
(68.0–94.7)
86.3
(76–2–100.1)**
t1:6 BMI (kg/m2) 22.7
(21.4–24.0)
22.5
(21.0–23.7)
23.4
(22.1–24.3)***
22.9
(21.6–24.1)
22.7
(21.3–23.9)
23.3
(22.1–24.3)**
28.8
(24.5–33.2)
29.8 ± 6.2 27.6 (24.5–31.1)*
t1:7 Waist circumference (cm) 78.0
(73.0–83.0)
75.5
(71.5–80.0)
84.5
(80.0–88.5)***
81.0 ± 7.2 78.2 ± 5.9 87.1 ± 5.7*** 96.9 ± 15.2 96.0 ± 16.3 98.4 ± 13.4
t1:8 fS total cholesterol (mmol/l) 4.9 (4.4–5.6) 4.9 (4.3–5.5) 5.1 ± 0.9** 5.4 (4.8–6.0) 5.4 ± 0.9 5.3 ± 0.9 4.9 (4.3–5.6) 4.8 (4.3–5.7) 4.9 (4.4–5.5)
t1:9 fS HDL-cholesterol (mmol/l) 1.5 (1.4–1.8) 1.6 (1.4–1.9) 1.4 (1.2–1.6)*** 1.6 (1.4–1.8) 1.7 ± 0.3 1.4 (1.3–1.6) *** 1.4 (1.2–1.7) 1.5 (1.2–1.8) 1.3 (1.1–1.6)***
t1:10 fS LDL-cholesterol (mmol/l) 3.0 (2.4–3.5) 2.8 (2.4–3.4) 3.2 ± 0.8*** 3.3 (2.8–3.9) 3.3 (2.8–3.9) 3.5 ± 0.8 3.0 (2.4–3.6) 2.9 (2.3–3.5) 3.1 ± 0.9
t1:11 fS triacylglycerol (mmol/l) 0.8 (0.6–1.0) 0.8 (0.6–1.0) 0.9 (0.7–1.1)*** 0.9 (0.7–1.1) 0.9 (0.7–1.2) 0.9 (0.7–1.2) 1.1 (0.8–1.6) 1.0 (0.7–1.5) 1.2 (0.9–1.6)*
t1:12 fP glucose (mmol/l) 5.5 (5.2–5.7) 5.4 ± 0.3 5.6 (5.4–5.8)*** 5.6 (5.4–5.8) 5.6 (5.3–5.8) 5.7 ± 0.2*** 5.4 (5.0–5.8) 5.4 ± 0.6 5.5 ± 0.5*
t1:13 fS insulin (pmol/l) 24.6
(19.8–31.8)
25.2
(20.4–32.4)
24.0 (19.2–30.6)* 27.0
(20.4–33.6)
27.0
(21.6–33.6)
27.0 (19.8–33.6) 40.2
(22.2–66.0)
38.4
(21.6–66.0)
42.0 (22.8–72.0)
t1:14 HOMA-IR 1.0 (0.8–1.3) 1.0 (0.8–1.3) 1.0 (0.8–1.3) 1.1 (0.8–1.4) 1.1 (0.8–1.4) 1.1 (0.8–1.4) 1.6 (0.8–2.7) 1.5 (0.8–2.5) 1.8 (0.9–3.2)
t1:15 Adjusted HOMA-IRa 1.0 (0.9–1.1) 1.0 (0.9–1.1) 1.0 (1.0–1.1)** 1.1 (1.0–1.2) 1.1 (1.0–1.2) 1.1 (1.1–1.2)** – – –
t1:16 HbA1c (%) – – – 5.1 (4.9–5.3) 5.1 (4.9–5.3) 5.2 (5.0–5.4)** 5.5 (5.3–5.7) 5.5 (5.3–5.7) 5.5 (5.2–5.7)
t1:17 HbA1c (mmol/mol) – – – 32 (30–34) 32 (30–34) 33 (31–36)** 37 (34–39) 37 (34–39) 37 (33–39)
t1:18 fS ALT (U/l) – – – 18 (15–23) 17 (14–22) 22 (16–28)*** 25 (18–39) 22 (16–31) 34 (23–53)***
t1:19 fS AST (U/l) – – – 22 (18–26) 21 (17–25) 24 (20–28)*** 26 (22–32) 24 (21–30) 29 (24–37)***
t1:20 fS GGT (U/l) – – – 19 (14–28) 17 (13–23) 23 (17–33)*** 23 (15–40) 19 (14–33) 30 (20–50)***
t1:21 PNPLA3I148M
(non-carrier/carrier, %)
59/41 59/41 60/40 60/40 63/37 53/47* 60/40 53/47 65/35
t1:22 Liver fat (%) – – – – – – 2.7 (0.9–8.6) 2.4 (0.8–7.1) 3.3 (1.1–12.4)*
Data are means ± SD (variables with normal distribution) or median (25–75%) (variables with non-normal distribution), unless otherwise stated
aAdjusted for BMI and age
*p < 0.05, **p < 0.005, ***p < 0.001 for men vs women within cohorts
fP, fasting plasma; fS, fasting serum
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431 cut-off of 1.9 was optimal for diagnosing NAFLD based on
432 the Youden index. A HOMA-IR of 2.0 corresponded to the
433 upper limit of normal liver fat content of 5.56%, as defined in
434 the DHS. A HOMA-IR value of 2.0 corresponded to HOMA-
435 IRs between 1.3 and 2.1 in six other laboratories, with an inter-
436 laboratory CVof 25%. These data show that the upper limit of
437 normal HOMA-IR closely corresponds to the upper limit of
438 liver fat defined as in the DHS, and that there is large inter-
439 laboratory variation in insulin measurements.
440 The upper limit of a reference value is usually defined in
441 population-based samples of healthy individuals as themean +
442 2 SD in normally distributed samples and as the 95th percen-
443 tile in non-normally distributed samples [12]. In this study, the
444 95th percentiles were 1.9 and 2.0 in the healthy individuals of
445 two population-based cohorts. Three previous studies have
446 been performed in healthy individuals. These studies were
447smaller (161 Japanese, 161 Italian and 312 Brazilian individ-
448uals) than the present study (459–1167 Finnish individuals)
449[14–16]. In the Japanese study [14], the 90th percentile of
450HOMA-IR was 1.7, which is comparable with that found in
451present study. In the Italian study, however, the participants
452were not healthy as they included diabetic and hypertensive
453individuals. The 80th percentile of HOMA-IR was 2.77 [16].
454This study used a non-specific RIA from Linco Research (St.
455Charles, MO, USA), which has produced the highest insulin
456concentrations of several insulin assays tested [17, 29].
457Similarly, the Brazilian study also used this RIA, and the
45890th percentile of HOMA-IR was equally high (2.71) [15].
459Thus, the higher HOMA-IR in these studies compared with
460the present study could be due to the inclusion of diabetic and
461hypertensive individuals in the Italian study, and to the use of
462an RIA that is no longer used in most laboratories [17].
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Fig. 1 Percentiles (90% CI) of
HOMA-IR in healthy men
(triangles and dotted/dashed
lines), women (squares and
dashed lines) and all individuals
(circles and solid lines) in the
population-based FINRISK/
DILGOM (a) and FIN-D2D
cohorts (b), and in I148M variant
non-carriers (PNPLA3I148II;
squares and dashed lines) and
carriers (PNPLA3I148IM/MM;
triangles and dotted/dashed lines)
and all individuals (circles and
solid lines) in the population-
based FINRISK/DILGOM (c)
and FIN-D2D cohorts (d)
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Fig. 2 Relationship between liver fat measured by 1H-MRS (log10) and
HOMA-IR (log10). (a) The relationship was similar (slopes p = 0.79,
elevations p = 0.75) in men (black circles) (r = 0.67, p < 0.001) and in
women (white circles) (r = 0.66, p < 0.001). The HOMA-IR correspond-
ing to normal liver fat (<5.56%), as defined in the DHS [18], was 2.0. (b)
There was a significant difference in the intercepts of the regression lines
(p = 0.007) between carriers (PNPLA3I148IM/MM) (r = 0.69, p < 0.001)
(black circles) and non-carriers (PNPLA3I148II) (r = 0.68, p < 0.001)
(white circles) of the I148M variant, showing that HOMA-IR was lower
for any given liver fat content in carriers than non-carriers. No significant
difference between the slopes was observed (p = 0.99)
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F463 We found no significant differences in HOMA-IR percen-
464 tiles between men and women among the healthy individuals
465 in either population-based cohort (Fig. 1). The men were,
466 however, slightly more obese and older than the women, and
467 therefore we also calculated age- and BMI-adjusted HOMA-
468 IRs. After adjustment, men had slightly higher HOMA-IRs
469 than women in both studies, but the differences in absolute
470 units were trivial (0.02 in FINRISK/DILGOM and 0.05 in the
471 FIN-D2D study; Table 1). Previous population-based studies
472 including healthy individuals have not reported HOMA-IRs
473 separately for men and women [14–16].
474 In keeping with the 95th percentile in healthy individuals in
475 the population-based cohorts, we found a HOMA-IR of 1.9 to
476 best distinguish non-diabetic individuals with and without
477 NAFLD. This value is similar to that found in 204 Brazilian
478 individuals [30]. As in the present study, in ROC analysis, a
479 HOMA-IR of 2.0 (AUROC 0.84) best distinguished between
480 NAFLD and non-NAFLD diagnosed by ultrasound or biopsy.
481In keeping with these data, a study comprising 263 Columbian
482men found a HOMA-IR of 1.7 (AUROC 0.78) to be the cut-
483off for NAFLD diagnosed by ultrasound [31]. In a recent
484population-based study in Iran, the best cut-off for NAFLD
485diagnosed by ultrasound was 2.0 in women and 1.8 in men
486[32]. Even though these results in different ethnic groups seem
487consistent, it will be important to perform studies in ethnic
488groups other than Finns.
489In linear regression analysis (Fig. 2), HOMA-IRs of 1.9
490and 2.0 corresponded to liver fat contents of 5.0% and
4915.56%. The latter value is identical to that defined as the upper
492limit of normal liver fat measured by 1H-MRS in the DHS
493[18]. The prevalence of NAFLD in the population-based
494DHS was 31% [33], which is comparable with that in our
495cohort of research volunteers (35%). In our cohort, the 95th
496percentile of liver fat in healthy individuals was 5.9%. This
497value is close to the 5.56% in the DHS [18]. However, as our
498liver fat cohort was not population-based, the 5.56% in the
499DHS can be considered more accurate than our estimate of
5005.9%.
501The PNPLA3 I148M variant predisposes to NAFLD but
502not to features of insulin resistance [34, 35]. Thus, despite an
503increased liver fat content in PNPLA3 I148M variant carriers,
504HOMA-IR has been reported to be similar in carriers and non-
505carriers of similar age, sex and BMI [36–39]. Consistent with
506these data, in the present two healthy population-based co-
507horts, no difference existed in clinical characteristics between
508carriers and non-carriers of the PNPLA3 I148M variant. The
509upper limit of normal HOMA-IR was the same for both
510groups. In the liver fat cohort, in which 35% of individuals
511had NAFLD, the optimal cut-off for distinguishing NAFLD
512from non-NAFLD was also not affected by genotype.
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Fig. 3 AUROC for HOMA-IR and NAFLD. The AUROC for HOMA-
IR was 0.88 (95% CI 0.84, 0.92) in the discovery group (solid line), 0.80
(0.70, 0.88) in the validation group (dashed line) and 0.85 (0.80, 0.89) in
all individuals (dotted line)
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513 However, when comparing carriers and non-carriers at a sim-
514 ilar liver fat content, carriers were found to have lower
515 HOMA-IR than non-carriers (Fig. 2b). These data imply that
516 HOMA-IR cannot be used to diagnose individuals with
517 NAFLD due to the PNPLA3 I148M variant, and that they
518 can only be identified by genotyping for this gene variant [10].
519 A limitation of HOMA-IR is that it is valid only as long as
520 serum insulin concentrations reflect merely insulin sensitivity,
521 not secretion [40–42]. In individuals with non-diabetic glu-
522 cose tolerance, fasting glucose and insulin concentrations are
523 closely positively correlated [43]. Once glucose tolerance be-
524 comes diabetic, insulin concentrations start to decline and
525 their relationship to glucose is inverse rather than positive
526 [6]. Under such conditions HOMA-IR underestimates insulin
527 resistance-associated NAFLD, although in a recent study in-
528 cluding 56 participants with type 2 diabetes, a HOMA-IR of
529 4.5 was estimated to be the optimal threshold for
530 distinguishing NAFLD diagnosed by ultrasound or computed
531 tomography [44]. The method used to measure insulin con-
532 centrations was not specified. The extreme example is type 1
533 diabetes, where there is no endogenous insulin. HOMA-IR is
534 also influenced by insulin clearance, unlike direct measure-
535 ments of insulin sensitivity. However, this may not be a prob-
536 lem as the decrease in insulin clearance closely parallels that in
537 hepatic insulin sensitivity [45].
538 Use of HOMA-IR in the clinic assumes the degree of inter-
539 laboratory variation in insulin assays is known [29]. In the
540 present study, we analysed fasting blood samples obtained
541 from ten individuals covering a wide range of HOMA-IRs
542 after a similar period of freezing and thawing and time of
543 storage. From the regression lines relating assay results be-
544 tween two laboratories (Fig. 4), the upper limit of normal
545 HOMA-IR was similar in Helsinki and Paris using the same
546 insulin assay (2.0), but was 1.3, 1.6, 1.8, 1.8 and 2.1 in the five
547 other laboratories using different assays. The inter-laboratory
548 CV was 25%. In contrast, the inter-laboratory CVs for other
549 analytes, with the exception of ferritin, were much lower and
550 ranged from 5% to 13%. This implies that every laboratory
551 should establish its own reference value for HOMA-IR, or at
552 least understand how its insulin assay compares with other
553 laboratories. Furthermore, reference values for HOMA-IR,
554 even in healthy individuals, and the relationship between
555 HOMA-IR and liver fat may be population-specific.
556 We conclude that the upper limit of HOMA-IR, defined
557 based on the identification of healthy individuals in two
558 population-based Finnish cohorts, closely corresponds to the
559 upper limit of normal liver fat content (<5.56%) found in the
560 DHS. This finding supports the use of HOMA-IR in identify-
561 ing individuals with ‘metabolic NAFLD’. The use of HOMA-
562 IR has, however, several limitations. HOMA-IR varies con-
563 siderably and more than other routine analytes among labora-
564 tories, particularly due to the use of different insulin assays. If
565 HOMA-IR were to be used as a surrogate for insulin
566resistance and NAFLD, insulin assays would need to be
567standardised. In addition, HOMA-IR underestimates liver fat
568content in individuals with NAFLD associated with the
569PNPLA3 I148M variant and, although not examined in this
570study, in individuals with defective insulin secretion.
571Acknowledgements We gratefully acknowledge A. Salo and A.
572Karioja-Kallio (Department of Medicine, Helsinki University Hospital),
573P. Pölönen (HUS Medical Imaging Center, Radiology, Helsinki
574University Hospital), M. L. Abate and C. Rosso (Department of
575Medical Sciences, University of Torino), M. Gaggini and E. Buzzigoli
576(Institute of Clinical Physiology, CNR Pisa, Italy), S. Depoix (I.
577Department of Medicine, University Medical Center Mainz), and D.
578Neeley and S. McLellen (Newcastle Hospitals NHS Foundation Trust)
579for skilful technical assistance; and volunteers for their help.
580
581Compliance with ethical standards
582Funding This study was supported by research grants from the
583Academy of Finland (HY-J), EU/EFPIA Innovative Medicines Initiative
584Joint Undertaking (EMIF grant no. 115372, HY-J), the Sigrid Juselius
585(HY-J), the Novo Nordisk Foundations (HY-J), EVO (HY-J), The Paulo
586Foundation (EI) and the Finnish Medical Foundation (EI). The authors
587are members of the EPoS (Elucidating Pathways of Steatohepatitis) con-
588sortium, which is funded by the Horizon 2020 Framework Program of the
589European Union under grant agreement 634413.
590Duality of interest The authors declare that there is no duality of inter-
591est associated with this manuscript.
592Contribution statement EI and YZ analysed the data. EI and HY-J
593interpreted the data and wrote the main text. EI, HY-J, EB, KC, AG,
594DS and QMA designed and EI, HY-J, EB, KC, DB-R, J-ML, AG, DS,
595JMS and QMA acquired data in and supervised the inter-laboratory insu-
596lin assay study. AH and NL performed and interpreted the 1H-MRS
597studies. MP, PJ, SM, SK-K and JS designed, performed and supervised
598the population-based FINRISK/DILGOM (PJ, SM) and FIN-D2D (SK-
599K, JS, MP) studies. HY-J designed and supervised the project. All authors
600have revised the manuscript critically for important intellectual content
601and approved the final version of the manuscript. HY-J is the guarantor of
602this work.
603Data availability The data that support the findings of this study are
604available from the corresponding author upon reasonable request.
605References 606
6071. Marchesini G, Brizi M, Bianchi G et al (2001) Nonalcoholic fatty
608liver disease: a feature of the metabolic syndrome. Diabetes 50:
6091844–1850
6102. Bugianesi E, Gastaldelli A, Vanni E et al (2005) Insulin resistance
611in non-diabetic patients with non-alcoholic fatty liver disease: sites
612and mechanisms. Diabetologia 48:634–642
6133. Matthews DR, Hosker JP, Rudenski AS et al (1985) Homeostasis
614model assessment: insulin resistance and beta-cell function from
615fasting plasma glucose and insulin concentrations in man.
616Diabetologia 28:412–419
6174. Wallace TM, Levy JC, Matthews DR (2004) Use and abuse of
618HOMA modeling. Diabetes Care 27:1487–1495
Diabetologia
JrnlID 125_ArtID 4340_Proof# 1 - 17/06/2017
AUTHOR'S PROOF!
U
N
C
O
R
R
E
C
T
E
D
P
R
O
O
F
619 5. Radziuk J (2000) Insulin sensitivity and its measurement: structural
620 commonalities among the methods. J Clin Endocrinol Metab 85:
621 4426–4433
622 6. Lillioja S, Mott DM, Howard BVet al (1988) Impaired glucose toler-
623 ance as a disorder of insulin action. N Engl J Med 318:1217–1225
624 7. Lillioja S, Mott DM, Spraul M et al (1993) Insulin resistance and
625 insulin secretory dysfunction as precursors of non-insulin-
626 dependent diabetes mellitus: prospective studies of Pima Indians.
627 N Engl J Med 329:1988–1992
628 8. Defronzo RA (2009) From the triumvirate to the ominous octet: a
629 new paradigm for the treatment of type 2 diabetes mellitus.
630 Diabetes 58:773–795
631 9. Gastaldelli A (2011) Role of beta-cell dysfunction, ectopic fat ac-
632 cumulation and insulin resistance in the pathogenesis of type 2
633 diabetes mellitus. Diabetes Res Clin Pract 93:S60–S65
634 10. European Association for the Study of the Liver (EASL), European
635 Association for the Study of Diabetes (EASD), European
636 Association for the Study of Obesity (EASO) (2016) EASL-
637 EASD-EASO clinical practice guidelines for the management of
638 non-alcoholic fatty liver disease. Diabetologia 59:1121–1140
639 11. Gräsbeck R, Alström T (1981) Reference values in laboratory med-
640 icine. The current state of the art. Wiley, Ann Arbor
641 12. Horn PS, Pesce AJ (2003) Reference intervals: an update. Clin
642 Chim Acta 334:5–23
643 13. Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone
644 G (1997) Insulin resistance and hypersecretion in obesity. European
645 Group for the Study of Insulin Resistance (EGIR). J Clin Invest
646 100:1166–1173
647 14. Nakai Y, FukushimaM, Nakaishi S et al (2002) The threshold value
648 for insulin resistance on homeostasis model assessment of insulin
649 sensitivity. Diabet Med 19:346–347
650 15. Geloneze B, Repetto EM, Geloneze SR, Tambascia MA, Ermetice
651 MN (2006) The threshold value for insulin resistance (HOMA-IR)
652 in an admixtured population IR in the Brazilian Metabolic
653 Syndrome Study. Diabetes Res Clin Pract 72:219–220
654 16. Bonora E, Kiechl S, Willeit J et al (1998) Prevalence of insulin
655 resistance in metabolic disorders: the Bruneck Study. Diabetes 47:
656 1643–1649
657 17. Manley SE, Stratton IM, Clark PM, Luzio SD (2007) Comparison
658 of 11 human insulin assays: implications for clinical investigation
659 and research. Clin Chem 53:922–932
660 18. Szczepaniak LS, Nurenberg P, Leonard D et al (2005) Magnetic
661 resonance spectroscopy to measure hepatic triglyceride content:
662 prevalence of hepatic steatosis in the general population. Am J
663 Physiol Endocrinol Metab 288:E462–E468
664 19. Anstee QM, Day CP (2015) The genetics of nonalcoholic fatty liver
665 disease: spotlight on PNPLA3 and TM6SF2. Semin Liver Dis 35:
666 270–290
667 20. Yki-Järvinen H (2014) Non-alcoholic fatty liver disease as a cause
668 and a consequence of metabolic syndrome. Lancet Diabetes
669 Endocrinol 2:901–910
670 21. Vartiainen E, Laatikainen T, Peltonen M et al (2010) Thirty-five-
671 year trends in cardiovascular risk factors in Finland. Int J Epidemiol
672 39:504–518
673 22. Saaristo T, Peltonen M, Keinänen-Kiukaanniemi S et al (2007)
674 National type 2 diabetes prevention programme in Finland: FIN-
675 D2D. Int J Circumpolar Health 66:101–112
676 23. Kotronen A, Peltonen M, Hakkarainen A et al (2009) Prediction of
677 non-alcoholic fatty liver disease and liver fat using metabolic and
678 genetic factors. Gastroenterology 137:865–872
679 24. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the
680 concentration of low-density lipoprotein cholesterol in plasma, without
681 use of the preparative ultracentrifuge. Clin Chem 18:499–502
682 25. Kotronen A, Johansson LE, Johansson LM et al (2009) A common
683 variant in PNPLA3, which encodes adiponutrin, is associated with
684 liver fat content in humans. Diabetologia 52:1056–1060
68526. Männistö S, Harald K, Kontto J et al (2014) Dietary and lifestyle
686characteristics associated with normal-weight obesity: the National
687FINRISK 2007 Study. Br J Nutr 111:887–894
68827. Hyysalo J, Männistö VT, Zhou Y et al (2014) A population-based
689study on the prevalence of NASH using scores validated against
690liver histology. J Hepatol 60:839–846
69128. Greiner M, Pfeiffer D, Smith RD (2000) Principles and practical
692application of the receiver-operating characteristic analysis for di-
693agnostic tests. Prev Vet Med 45:23–41
69429. Manley SE, Luzio SD, Stratton IM, Wallace TM, Clark PMS (2008)
695Preanalytical, analytical, and computational factors affect homeostasis
696model assessment estimates. Diabetes Care 31:1877–1883
69730. Salgado AL, Carvalho LD, Oliveira AC, Santos VN, Vieira JG,
698Parise ER (2010) Insulin resistance index (HOMA-IR) in the dif-
699ferentiation of patients with non-alcoholic fatty liver disease and
700healthy individuals. Arq Gastroenterol 47:165–169
70131. Perez M, Gonzáles L, Olarte R et al (2011) Nonalcoholic fatty liver
702disease is associated with insulin resistance in a young Hispanic
703population. Prev Med 52:174–177
70432. Motamed N, Miresmail SJH, Rabiee B et al (2016) Optimal cutoff
705points for HOMA-IR and QUICKI in the diagnosis of metabolic
706syndrome and non-alcoholic fatty liver disease: a population based
707study. J Diabetes Complicat 30:269–274
70833. Browning JD, Szczepaniak LS, Dobbins R et al (2004) Prevalence
709of hepatic steatosis in an urban population in the United States:
710impact of ethnicity. Hepatology 40:1387–1395
71134. Sookoian S, Pirola CJ (2011) Meta-analysis of the influence of
712I148M variant of patatin-like phospholipase domain containing 3
713gene (PNPLA3) on the susceptibility and histological severity of
714nonalcoholic fatty liver disease. Hepatology 53:1883–1894
71535. Petäjä EM, Yki-Järvinen H (2016) Definitions of normal liver fat
716and the association of insulin sensitivity with acquired and genetic
717NAFLD—a systematic review. Int J Mol Sci 17:E633
71836. Verrijken A, Beckers S, Francque S et al (2013) A gene variant of
719PNPLA3, but not of APOC3, is associated with histological param-
720eters of NAFLD in an obese population. Obesity 21:2138–2145
72137. Romeo S, Sentinelli F, Cambuli VMet al (2010) The 148M allele of
722the PNPLA3 gene is associated with indices of liver damage early
723in life. J Hepatol 53:335–338
72438. Valenti L, Alisi A, Galmozzi E et al (2010) I148M patatin-like
725phospholipase domain-containing 3 gene variant and severity of
726pediatric nonalcoholic fatty liver disease. Hepatology 52:1274–
7271280
72839. Del Ben M, Polimeni L, Brancorsini M et al (2014) Non-alcoholic
729fatty liver disease, metabolic syndrome and patatin-like phospholi-
730pase domain-containing protein3 gene variants. Eur J Intern Med
73125:566–570
73240. Singh B, SaxenaA (2010) Surrogate markers of insulin resistance: a
733review. World J Diabetes 1:36–47
73441. Borai A, Livingstone C, Farzal A, Kholeif M, Wang T, Ferns G
735(2010) Reproducibility of HOMA and QUICKI among individuals
736with variable glucose tolerance. Diabetes Metab 36:247–249
73742. Bonora E, Targher G, Alberiche M et al (2000) Homeostasis model
738assessment closely mirrors the glucose clamp technique in the as-
739sessment of insulin sensitivity: studies in subjects with various de-
740grees of glucose tolerance and insulin sensitivity. Diabetes Care 23:
74157–63
74243. Defronzo RA, Bonadonna RC, Ferrannini E (1992) Pathogenesis of
743NIDDM: a balanced overview. Diabetes Care 15:318–368
74444. Gutierrez-Buey G, Núñez-Córdoba JM, Llavero-Valero M,
745Gargallo J, Salvador J, Escalada J (2017) Is HOMA-IR a potential
746screening test for non-alcoholic fatty liver disease in adults with
747type 2 diabetes? Eur J Intern Med. doi:10.1016/j.ejim.2017.03.006
74845. Kotronen A, Vehkavaara S, Seppälä-Lindroos A et al (2007) Effect
749of liver fat on insulin clearance. Am J Physiol Endocrinol Metab
750293:E1709–E1715
751
Diabetologia
JrnlID 125_ArtID 4340_Proof# 1 - 17/06/2017
AUTHOR'S PROOF!
U
N
C
O
R
R
E
C
T
E
D
P
R
O
O
F
AUTHOR QUERY
AUTHOR PLEASE ANSWER QUERY.
No Query.
